AspenBio diagnostic news

AspenBio said that four directors resigned from its board as part of a restructuring that began in mid-2011 to focus on developing its AppyScore appendicitis test. The resignations include Douglas Hepler, Michael Merson, Mark Ratain and Gregory Pusey, who will remain VP. AspenBio plans to begin a pivotal trial with AppyScore next quarter. The company said it will look to appoint additional non-employee directors, but plans to keep the board at a smaller size than before the resignations. AppyScore is a multi-marker, blood-based test panel consisting of the S100 calcium binding protein A8 ( S100A8; calgranulin A; MRP8) and MRP14 biomarkers and C-reactive protein (CRP), plus a white blood cell count. ...